Aaron F. Barkoff
Aaron F. Barkoff
Stop FollowingAaron F. Barkoff
View as an RSS Feed
View Aaron F. Barkoff's Articles BY TICKER:
- District Court Delivers Good News to Mylan, Barr in Amrix Litigation
- What's Next for Mylan After Court Dismisses Company's Complaint Against FDA?
-
Book Review: 'The Generic Challenge: Understanding Patents, FDA and Pharmaceutical Life-Cycle Management'
on Mon, May 2, 2011 • Comment!
- AstraZeneca Defeats Teva's Unusual Patent Claim
- Dr. Reddy's Wins Attorney Fees From AstraZeneca in Prilosec OTC Case
- District Court Denies Teva's Motion to Stay Integrelin Case
- Federal Circuit Vacates Injunction That Directed Novo Nordisk to Revise Patent Use Code for Prandin
- Pharmas Walking the Patent Tightrope
- Bayer Patent on Yasmin Affirmed Invalid
- Supreme Court Denies Aventis' Cert Petition in Lovenox Case
- Federal Circuit Affirms Extension of Stay Against Teva's Generic Evista
- Federal Circuit Affirms Fee Award to Takeda
- Federal Circuit Affirms Merck’s Victory in Trusopt/Cosopt Case
- District Court Affirms Dismissal of Prasco's Declaratory Judgment Suit Against Medicis
- KV Pharmaceutical's Motion for Rule 11 Sanctions in Ritalin LA Case Denied
-
Eisai Victorious Over Teva and Dr. Reddy’s in Aciphex Compound Patent Case
- Merck Victorious over Apotex in Fosamax Counterclaims Case
- Summary Judgment in Seroquel Case Favors AstraZeneca; Teva and Sandoz to Appeal
- Roche and Allergan Victorious Over Apotex in Acular LS Dispute
- Barr and Mylan Invalidate Boehringer Ingelheim's Patent on Mirapex
- Teva Granted Final Approval of Risperidone ANDA; Launches with 180-Day Exclusivity
- FDA Denies King Pharma's Citizen Petition on Altace; Approves Ramipril ANDAs
- Mylan Prevails Over AstraZeneca in Appeal of Prilosec Case
- King Pharmaceuticals Files Citizen Petition Relating to New Altace Patent
- Apotex Sues FDA to Recover Its 180-Day Exclusivity on Generic Plavix
- Impax's Declaratory Judgment Complaint in ANDA Case Against Medicis Dismissed
- Validity of Takeda's Prevacid Patents Upheld; Teva's Obviousness Arguments Rejected
- Court Affirms Decision Protecting Ortho-McNeil's Topamax Against Mylan's Generic
- Federal Circuit Rules in Favor of Forest in Dispute with Caraco over Lexapro
- Eisai Wins Preliminary Injunction Against Teva's Generic Altheimer's Drug
- Court Sides with Amgen in European-Produced EPO Dispute with Roche
- Court Upholds P&G's Actonel Patent; Rejects Teva's Obviousness Arguments
